Tegaserod

A new 5-HT4 agonist

B. E. Lacy, Shaoyong Yu

Research output: Contribution to journalArticle

Abstract

Tegaserod is a medication that has been shown to be of benefit in women with irritable bowel syndrome (IBS) associated with abdominal pain, bloating, and constipation. Tegaserod is a selective serotonin receptor subtype 4 partial agonist designed to interact with the network of cells and nerves throughout the gastrointestinal tract that use serotonin. Tegaserod has been shown to modulate both gastrointestinal motility and visceral sensitivity. Specifically, it increases the peristaltic reflex and decreases visceral sensitivity. Clinical studies have shown that tegaserod improves symptoms of abdominal pain, bloating, and constipation in women with IBS. This article discusses the role of serotonin in gastrointestinal tract physiology, the structure and pharmacokinetic profile of tegaserod, and clinical applications of this new drug.

Original languageEnglish (US)
Pages (from-to)27-33
Number of pages7
JournalJournal of Clinical Gastroenterology
Volume34
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Serotonin 5-HT4 Receptor Agonists
Irritable Bowel Syndrome
Constipation
Abdominal Pain
Gastrointestinal Tract
Serotonin
Receptors, Serotonin, 5-HT4
Gastrointestinal Motility
Reflex
Pharmacokinetics
tegaserod
Neurons
Pharmaceutical Preparations

Keywords

  • Constipation
  • Irritable bowel syndrome
  • Serotonin
  • Tegaserod
  • Zelnorm

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Tegaserod : A new 5-HT4 agonist. / Lacy, B. E.; Yu, Shaoyong.

In: Journal of Clinical Gastroenterology, Vol. 34, No. 1, 2002, p. 27-33.

Research output: Contribution to journalArticle

Lacy, B. E. ; Yu, Shaoyong. / Tegaserod : A new 5-HT4 agonist. In: Journal of Clinical Gastroenterology. 2002 ; Vol. 34, No. 1. pp. 27-33.
@article{b69a2261c1534f1b9800b3e2a45c0d12,
title = "Tegaserod: A new 5-HT4 agonist",
abstract = "Tegaserod is a medication that has been shown to be of benefit in women with irritable bowel syndrome (IBS) associated with abdominal pain, bloating, and constipation. Tegaserod is a selective serotonin receptor subtype 4 partial agonist designed to interact with the network of cells and nerves throughout the gastrointestinal tract that use serotonin. Tegaserod has been shown to modulate both gastrointestinal motility and visceral sensitivity. Specifically, it increases the peristaltic reflex and decreases visceral sensitivity. Clinical studies have shown that tegaserod improves symptoms of abdominal pain, bloating, and constipation in women with IBS. This article discusses the role of serotonin in gastrointestinal tract physiology, the structure and pharmacokinetic profile of tegaserod, and clinical applications of this new drug.",
keywords = "Constipation, Irritable bowel syndrome, Serotonin, Tegaserod, Zelnorm",
author = "Lacy, {B. E.} and Shaoyong Yu",
year = "2002",
doi = "10.1097/00004836-200201000-00006",
language = "English (US)",
volume = "34",
pages = "27--33",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Tegaserod

T2 - A new 5-HT4 agonist

AU - Lacy, B. E.

AU - Yu, Shaoyong

PY - 2002

Y1 - 2002

N2 - Tegaserod is a medication that has been shown to be of benefit in women with irritable bowel syndrome (IBS) associated with abdominal pain, bloating, and constipation. Tegaserod is a selective serotonin receptor subtype 4 partial agonist designed to interact with the network of cells and nerves throughout the gastrointestinal tract that use serotonin. Tegaserod has been shown to modulate both gastrointestinal motility and visceral sensitivity. Specifically, it increases the peristaltic reflex and decreases visceral sensitivity. Clinical studies have shown that tegaserod improves symptoms of abdominal pain, bloating, and constipation in women with IBS. This article discusses the role of serotonin in gastrointestinal tract physiology, the structure and pharmacokinetic profile of tegaserod, and clinical applications of this new drug.

AB - Tegaserod is a medication that has been shown to be of benefit in women with irritable bowel syndrome (IBS) associated with abdominal pain, bloating, and constipation. Tegaserod is a selective serotonin receptor subtype 4 partial agonist designed to interact with the network of cells and nerves throughout the gastrointestinal tract that use serotonin. Tegaserod has been shown to modulate both gastrointestinal motility and visceral sensitivity. Specifically, it increases the peristaltic reflex and decreases visceral sensitivity. Clinical studies have shown that tegaserod improves symptoms of abdominal pain, bloating, and constipation in women with IBS. This article discusses the role of serotonin in gastrointestinal tract physiology, the structure and pharmacokinetic profile of tegaserod, and clinical applications of this new drug.

KW - Constipation

KW - Irritable bowel syndrome

KW - Serotonin

KW - Tegaserod

KW - Zelnorm

UR - http://www.scopus.com/inward/record.url?scp=0036138537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036138537&partnerID=8YFLogxK

U2 - 10.1097/00004836-200201000-00006

DO - 10.1097/00004836-200201000-00006

M3 - Article

VL - 34

SP - 27

EP - 33

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 1

ER -